GW Pharmaceuticals Patenting THC and CBD for Brain Cancer

Health
GW Pharmaceuticals Receives Patent Approval for THC and CBD Usage in Brain Cancer Treatment

Clinical research and anecdotal reports have indicated the use of cannabis and cannabis-derived chemicals to fight an array of cancers for a long time. Drug company GW Pharmaceuticals recently announced that the U.S. Patent Office has issued it a Notice of Allowance for a patent application involving the use of two main marijuana chemicals, tetrahydrocannabinol (THC) and cannabidiol (CBD) for treating gliomas.

Last month, this drug maker who specializes in cannabis-based pharmaceuticals also launched the first clinical trial to investigate the effectiveness of their cannabis drug Sativex in combination with Temozolomide, the standard chemotherapy drug. The trial involves 20 patients diagnosed with an aggressive and rare form of brain cancer known as recurrent glioblastoma multiforme (GBM). GW Pharmaceuticals has received early approval for their patent application that was filed in 2009, listing Otsuka Pharmaceutical as a collaborator.

The subject patent specifically covers a glioma treatment method for humans using a combination of THC and CBD in a ratio from 1:1 to 1:20 (THC: CBD) with goal to reduce tumor volume and cell viability, or inhibit cell growth. In November, the company also announced that it had started human trials of a CBD-rich cannabis drug for the treatment of pediatric epilepsy.